oasis 1 oral semaglutide 50 mg obesity nejm 2023 Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity

50 mg of oral #semaglutide daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or #obesity, with or without type 2 #diabetes. https://ja.ma/41sPiYj

28.03

★★★★☆4.8 (126)

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

29.18

★★★★★4.9 (98)

FDA has approved a new oral form of semaglutide for long-term weight reduction in adults with obesity or overweight. The new oral tablet is also indicated for reducing the risk of major

21.59

★★★★★5.0 (157)

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

24.40

★★★★★4.7 (84)

VisualAbstract:Oral semaglutide effectively reduces bodyweight in non-diabetic adults with obesity

27.77

★★★★★4.9 (203)

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

25.29

★★★★★5.0 (176)

Study reveals oral Semaglutide 50 mg as promising treatment for obesity in adults: the Lancet report

25.43

★★★★★4.8 (132)